Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
2(67%)

Phase Distribution

Ph early_phase_1
2
67%
Ph phase_2
1
33%

Phase Distribution

2

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Early Phase 1First-in-human
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(1)
Terminated(2)

Detailed Status

Terminated2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
33.3%
Most Advanced
Phase 2

Trials by Phase

Early Phase 12 (66.7%)
Phase 21 (33.3%)

Trials by Status

completed133%
terminated267%

Recent Activity

0 active trials
Showing 3 of 3
terminatedearly_phase_1

Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases

NCT03724409
completedearly_phase_1

Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor

NCT03197012
terminatedphase_2

Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell Lymphomas

NCT02488512

Clinical Trials (3)

Showing 3 of 3 trials
NCT03724409Early Phase 1

Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases

Terminated
NCT03197012Early Phase 1

Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor

Completed
NCT02488512Phase 2

Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell Lymphomas

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3